Politics

/

ArcaMax

Commentary: Medical breakthroughs shouldn't take decades

Kevin J. Morrison, Los Angeles Times on

Published in Op Eds

In 2004, California voters authorized $3 billion to create the California Institute for Regenerative Medicine.

In 2026, the institute released its first therapy, a treatment for children with a rare immune disorder. For those children and their families, that achievement was life-changing.

But it took too long.

I have ALS. Twenty-two years is a time horizon I cannot reasonably plan around. Neither can people facing cancer, Alzheimer’s or other deadly diseases.

Now, Proposition 38 will invest another $8.4 billion in medical research. With those billions, California must ask for faster results.

It’s a reasonable request, in light of advancements in medical research.

Remember “Operation Warp Speed” to develop, manufacture and distribute COVID-19 vaccines? In January 2020, scientists began working with the virus. In December, the Food and Drug Administration rolled out a vaccine to the public.

Primitive artificial intelligence helped. Today, AI is orders of magnitude more powerful than it was in 2020.

AI evaluates vast datasets, maps genetic mutations and assists in drug design. It uncovers subtle patterns that humans overlook. For example, it flags breast cancers that diagnosticians have missed.

The White House is prioritizing AI development. At the same time, the FDA is encouraging drug testing through other technologies, such as synthetic organoids. These small devices mimic human organs and catch toxic reactions much earlier than traditional animal testing.

Why is this important? About 9 out of 10 drugs pass animal tests but eventually fail in human trials. Those failures consume years. The California Institute for Regenerative Medicine’s breakthrough treatment for that rare childhood disorder suffered multi-year setbacks because of faulty animal trials.

How many kids would have been helped if the development timeframe had been two years instead of 22 years?

Another problem is false success, and one example is striking: For 30 years, hundreds of drugs successfully reversed Alzheimer’s pathology in mice. But every one of those “cures” failed in people. Another waste of precious time.

Despite today’s better tools, as well as federal encouragement, most institutions remain slow to modernize. In the minds of many research administrators, drugs are still on 20-year development cycles.

But what if California made faster drug development a requirement for receiving the state’s investment dollars?

The regenerative medicine institute is showing how that’s possible, speeding up its pipeline by tying programs to funding milestones. Its goal is to move quickly through FDA clearance and complete each trial within strict two-year timelines.

Other major research institutions are also emphasizing speed. Stanford University has accelerated its drug pipelines by prioritizing human-tissue screening, bypassing traditional animal tests by validating drugs directly on human cells.

 

Scripps Research Institute has leveraged an explosion of research data by combining it with AI workflows. Processing that once took months now takes days.

This momentum matters.

California should demand the speed that technology can deliver. Scientists can access AI through public tools, university systems, commercial services and collaborations. They just need an incentive – and funding – to do it.

But the other part is getting the data and expertise needed to use AI well. We can address those challenges through additional requirements for publicly funded research.

What if we demanded modernized human-centric pipelines, just like the FDA suggests? That would connect research to patients from the get-go.

Beyond technologies and techniques, we should demand that researchers share findings to allow others to build on them right away. A discovery trapped in an institutional silo cannot help other scientists create a robust solution or avoid repeating an expensive mistake.

The central question is straightforward: What can public investment require that otherwise would not happen?

When each application at a publicly funded institution identifies a problem and explains the proposed advance, it should establish accountability milestones and avoid decades of churn.

This includes challenges beyond therapies. For basic research, progress might resolve a biological question or create a reliable tool. Even those results can be incentivized by a specific timeframe.

There should be no open-ended project timelines funded by California dollars.

Despite the passage of Proposition 38, I fear a future in which disappointed voters become unwilling to finance research. Protecting their confidence is part of protecting our chance at treatment.

California’s billions should fund a research system that learns faster, shares discoveries sooner and moves promising treatments toward patients with urgency.

Every institution receiving public money should answer a question that patients ask every day: What are you doing to shorten our wait?

____

Kevin J. Morrison is a San Francisco-based writer and ALS activist.


©2026 Los Angeles Times. Visit at latimes.com. Distributed by Tribune Content Agency, LLC.

 

Comments

blog comments powered by Disqus

 

Related Channels

The ACLU

ACLU

By The ACLU
Armstrong Williams

Armstrong Williams

By Armstrong Williams
Austin Bay

Austin Bay

By Austin Bay
Betsy McCaughey

Betsy McCaughey

By Betsy McCaughey
Bill Press

Bill Press

By Bill Press
Bonnie Jean Feldkamp

Bonnie Jean Feldkamp

By Bonnie Jean Feldkamp
Cal Thomas

Cal Thomas

By Cal Thomas
Clarence Page

Clarence Page

By Clarence Page
Danny Tyree

Danny Tyree

By Danny Tyree
David Harsanyi

David Harsanyi

By David Harsanyi
Dick Polman

Dick Polman

By Dick Polman
Erick Erickson

Erick Erickson

By Erick Erickson
Froma Harrop

Froma Harrop

By Froma Harrop
Jacob Sullum

Jacob Sullum

By Jacob Sullum
Jamie Stiehm

Jamie Stiehm

By Jamie Stiehm
Jeff Robbins

Jeff Robbins

By Jeff Robbins
Jessica Johnson

Jessica Johnson

By Jessica Johnson
Jim Hightower

Jim Hightower

By Jim Hightower
Joe Conason

Joe Conason

By Joe Conason
John Stossel

John Stossel

By John Stossel
Josh Hammer

Josh Hammer

By Josh Hammer
Judge Andrew P. Napolitano

Judge Andrew Napolitano

By Judge Andrew P. Napolitano
Laura Hollis

Laura Hollis

By Laura Hollis
Marc Munroe Dion

Marc Munroe Dion

By Marc Munroe Dion
Michael Barone

Michael Barone

By Michael Barone
Mona Charen

Mona Charen

By Mona Charen
Rachel Marsden

Rachel Marsden

By Rachel Marsden
Rich Lowry

Rich Lowry

By Rich Lowry
Robert B. Reich

Robert B. Reich

By Robert B. Reich
Ruben Navarrett Jr.

Ruben Navarrett Jr

By Ruben Navarrett Jr.
Ruth Marcus

Ruth Marcus

By Ruth Marcus
S.E. Cupp

S.E. Cupp

By S.E. Cupp
Salena Zito

Salena Zito

By Salena Zito
Star Parker

Star Parker

By Star Parker
Stephen Moore

Stephen Moore

By Stephen Moore
Susan Estrich

Susan Estrich

By Susan Estrich
Ted Rall

Ted Rall

By Ted Rall
Terence P. Jeffrey

Terence P. Jeffrey

By Terence P. Jeffrey
Tim Graham

Tim Graham

By Tim Graham
Tom Purcell

Tom Purcell

By Tom Purcell
Veronique de Rugy

Veronique de Rugy

By Veronique de Rugy
Victor Joecks

Victor Joecks

By Victor Joecks
Wayne Allyn Root

Wayne Allyn Root

By Wayne Allyn Root

Comics

Jeff Danziger Marshall Ramsey Al Goodwyn John Branch Dave Whamond Lee Judge